On Thursday, Amicus Therapeutics, Inc. (NASDAQ:FOLD)’s shares declined -16.88% to $15.12.
Amicus Therapeutics (FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, declared financial results for the second quarter ended June 30, 2015. The Company also offered program updates and reiterated full-year 2015 net cash spend guidance of $100 million to $110 million.
Financial Highlights for Second Quarter Ended June 30, 2015
- Cash, cash equivalents, and marketable securities totaled $361.4 million at June 30, 2015, contrast to $169.1 million at December 31, 2014.
- Total operating expenses raised to $26.9 million contrast to $14.7 million for the second quarter 2014, primarily due to enhances in preclinical and clinical development costs on the Fabry monotherapy and Pompe ERT programs.
- Net loss was $27.1 million, or $0.27 per share, contrast to a net loss of $14.6 million, or $0.22 per share, for the second quarter 2014.
Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for various rare and orphan diseases. Its product candidate is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The companys development programs comprise next-generation ERTs for lysosomal storage disorders (LSDs), such as Fabry disease, Pompe disease, and Mucopolysaccharidosis Type I.
Allergan PLC (NYSE:AGN)’s shares dropped -5.06% to $319.61.
Allergan plc (AGN) stated continued exceptional performance with net revenue increasing 116 percent to $5.76 billion for the quarter ended June 30, 2015, contrast to $2.67 billion in the second quarter 2014. On a non-GAAP basis, diluted earnings per share raised 29 percent to $4.41 for the second quarter 2015, contrast to $3.42 in the second quarter 2014. GAAP loss per share for the second quarter 2015 was $0.80, contrast to GAAP income per diluted share of $0.28 in the preceding year period. GAAP results were influenced by amortization, in-process research and development impairments, acquisition-related expenses, acquisition accounting valuation related expenses and severance and integration costs associated with attained businesses, mainly the acquisitions of Allergan on March 17, 2015 and Forest Laboratories on July 1, 2014.
American Capital Agency Corp. operates as a real estate investment trust (REIT) in the United States. The company invests in residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by government-sponsored enterprise or by the United States government agency. It funds its investments primarily through short-term borrowings structured as repurchase agreements.
At the end of Thursday’s trade, Royal Dutch Shell plc (ADR) (NYSE:RDS.A)‘s shares surged 1.49% to $58.57.
Royal Dutch Shell plc (RDS-A) declared that its recommended combination with BG Group plc (“BG”) has received unconditional merger clearance from the Brazilian competition authority (CADE), satisfying the first of the pre-conditions to the combination. Other pre-conditions comprise merger clearances in Australia, China and Europe.
Following comments made in June, when the recommended combination cleared its first antitrust hurdle in the United States, van Beurden also recently re-confirmed the filing process is well underway in the remaining pre-conditional and other jurisdictions, and the recommended combination remains on track to complete in early 2016. The pre-conditions and conditions to the combination are set out in the 8 April deal declarement.
Royal Dutch Shell plc operates as an independent oil and gas company worldwide. It operates through Upstream and Downstream segments. The company explores for and extracts crude oil, natural gas, and natural gas liquids. It also converts natural gas to liquids to provide fuels and other products; markets and trades natural gas; extracts bitumen from mined oil sands and converts it to synthetic crude oil; and generates electricity from wind energy.
Amgen, Inc. (NASDAQ:AMGN), ended its Thursday’s trading session with -3.84% loss, and closed at $169.66.
Amgen (AMGN) declared positive interim results from its open-label extension of the global Phase 2, double-blind, placebo-controlled study evaluating the safety and efficacy of AMG 334 for the prevention of episodic migraine. Patients who entered the open-label phase received AMG 334 70 mg monthly and practiced a sustained reduction in monthly migraine days at week 52.
At one year, patients receiving AMG 334 70 mg practiced an average of a -4.9-day reduction from a baseline of 8.7 mean monthly migraine days, regardless of treatment received during the blinded phase. The 50 percent responder rate (greater than 50 percent reduction in monthly migraine days) was 62 percent at 52 weeks. Additional responder rates were stated for the first time: at 52 weeks the 75 percent responder rate was 38 percent and the 100 percent responder rate was 19 percent.
Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine. The company’s principal products comprise Neulasta, a pegylated protein to decrease the incidence of infection associated with chemotherapy-induced febrile neutropenia in cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection as manifested by febrile neutropenia for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. Its principal products also comprise EPOGEN for the treatment of dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in chronic kidney disease patients on dialysis. The company’s other marketed products comprise Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; Vectibix, a human monoclonal antibody; and BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It also develops various products that are in various clinical trials.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
